Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NUVB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Taletrectinib (AB-106) FDA approved Jun 2025 · Ibtrozi |
Non Small Cell Lung Cancer | Phase 3 · NCT06564324 | Recruiting |
| Safusidenib | Glioma | Phase 3 · NCT05303519 | Recruiting |
| Drug-drug Conjugate NUV-1511 | Advanced Solid Tumor | Phase 1/2 · NCT06334432 | Active not recruiting |
| Inixaciclib (NUV-422) | Advanced Breast Cancer | Phase 1/2 · NCT05191004 | Withdrawn |
| BD2-selective BET Inhibitor NUV-868 | Advanced Solid Tumor | Phase 1 · NCT05252390 | Terminated |
| Multiple administration of omeprazole Single… | Pharmacokinetic Study | Phase 1 · NCT05609929 | Completed |
| Part A: Safusidenib Erbumine | Glioma | Early Phase 1 · NCT05577416 | Completed |
| Part B: Safusidenib Erbumine | Glioma | Early Phase 1 · NCT05577416 | Completed |
| Cancer treatment with tyrosine kinase… | Cancer | N/A · NCT04151342 | Recruiting |
Also used in these trials (approved or third-party drugs, not NUVB's own candidates): Crizotinib, Enzalutamide, Fulvestrant, Olaparib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NUVB holds $725.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.8M/quarter from operations, an estimated runway of 53.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUVB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| David Hung PRESIDENT AND CEO, Director, 10% owner · +2.00M options |
Insider | 59,281,054 | 16.79% | 2025-06-16 |
| FMR, LLC | Institution (13F) | 52,230,295 | 14.80% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 27,630,837 | 7.83% | 2026-06-30 |
| Decheng Capital LLC | Institution (13F) | 25,954,439 | 7.35% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 11,919,514 | 3.38% | 2026-06-30 |
| Omega Fund Management, Llc | Institution (13F) | 8,081,089 | 2.29% | 2026-06-30 |
| Laurion Capital Management, LP | Institution (13F) | 7,820,013 | 2.22% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 7,370,794 | 2.09% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 6,244,805 | 1.77% | 2026-06-30 |
| Duquesne Family Office Llc | Institution (13F) | 4,539,800 | 1.29% | 2026-06-30 |
| American Century Companies Inc | Institution (13F) | 4,499,643 | 1.27% | 2026-06-30 |
| Robert Mashal Director · +864,576 options |
Insider | 225,000 | 0.06% | 2026-06-09 |
Share count 353,017,638 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-19 filed 2026-08-21 |
Hattersley Gary |
Sale (S) | 100,000 | $7.09 | 0 |
| 2026-08-19 filed 2026-08-21 |
Hattersley Gary |
Option exercise (M) | 100,000 | $1.87 | 100,000 |
| 2026-08-19 filed 2026-08-21 |
Hattersley Gary |
Option exercise (M) | 100,000 | – | – |
| 2026-07-15 filed 2026-07-17 |
Sauvage Philippe |
Option exercise (M) | 1 | – | – |
| 2026-07-15 filed 2026-07-17 |
Sauvage Philippe |
Option exercise (M) | 39,999 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUVB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →